CV CapsoVision, Inc
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1378325 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-29.6%
TTM EPS YoY87.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin49.7%
Operating margin-212.1%
Net margin-210.1%
FCF margin-210.3%
EBITDA margin-210.4%
Returns
ROE-125.0%
ROA-100.1%
ROIC (approx.)-99.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets19.5%
Debt / equity0.00x
Current ratio5.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.2%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.57M | $3.64M | $2.79M | $3.92M | $3.54M | $3.31M | $2.78M | $3.45M |
| Cost of revenue | $1.80M | $1.77M | $1.46M | $1.96M | $1.62M | $1.50M | $1.29M | $1.72M |
| Gross profit | $1.76M | $1.87M | $1.33M | $1.95M | $1.91M | $1.81M | $1.49M | $1.73M |
| R&D expense | $4.80M | $5.31M | $4.43M | $5.72M | $6.09M | $3.39M | $3.11M | $3.12M |
| SG&A expense | $2.29M | $2.21M | $1.90M | $1.75M | $2.07M | $1.22M | $1.81M | $1.45M |
| Operating income | -$7.38M | -$7.58M | -$7.09M | -$7.46M | -$8.02M | -$4.65M | -$5.38M | -$4.63M |
| Pretax income | -$7.34M | -$7.48M | -$7.03M | -$7.37M | -$7.92M | -$4.62M | -$5.38M | -$4.63M |
| Income tax | $0 | $0 | $0 | $24,000 | $0 | $0 | $0 | $11,000 |
| Net income | -$7.34M | -$7.48M | -$7.03M | -$7.39M | -$7.92M | -$4.62M | -$5.38M | -$4.64M |
| EBITDA | -$7.33M | -$7.52M | -$7.04M | -$7.41M | -$7.96M | -$4.60M | -$5.33M | -$4.58M |
| EPS (basic) | -0.15 | -0.15 | -0.15 | — | -0.17 | -2.02 | -2.49 | — |
| EPS (diluted) | -0.15 | -0.15 | -0.15 | — | -0.17 | -2.02 | -2.49 | — |
| Weighted avg. shares (diluted) | 50.57M | 49.94M | 47.46M | — | 46.22M | 2.29M | 2.16M | — |
| Balance sheet | ||||||||
| Receivables | $2.46M | $2.27M | $1.93M | $2.50M | $1.87M | $1.85M | — | $2.00M |
| Inventory | $4.75M | $4.70M | $3.49M | $2.99M | $3.19M | $3.04M | — | $2.63M |
| Current assets | $31.05M | $17.28M | $24.50M | $16.67M | $24.05M | $7.80M | — | $14.85M |
| PP&E, net | $508,000 | $562,000 | $620,000 | $611,000 | $640,000 | $683,000 | — | $720,000 |
| Total assets | $32.75M | $18.57M | $25.95M | $18.16M | $25.66M | $9.55M | — | $16.80M |
| Current liabilities | $6.12M | $5.16M | $5.36M | $4.43M | $4.63M | $4.22M | — | $1.80M |
| Total liabilities | $6.38M | $5.40M | $5.72M | $4.90M | $5.22M | $4.91M | — | $2.69M |
| Shareholders' equity | $26.37M | $13.17M | $20.22M | $13.26M | $20.44M | -$138.99M | -$134.70M | -$129.51M |
| Shares outstanding | 53.57M | 50.03M | 49.84M | 46.87M | 46.80M | 2.46M | — | 2.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.04M | -$8.40M | -$6.07M | -$7.69M | -$5.67M | -$4.53M | -$4.99M | -$5.40M |
| Capital expenditure | $22,000 | $0 | $48,000 | $8,000 | $12,000 | $30,000 | $40,000 | $0 |
| Free cash flow | -$7.06M | -$8.40M | -$6.11M | -$7.69M | -$5.68M | -$4.56M | -$5.03M | -$5.40M |
| Investing cash flow | -$22,000 | $0 | -$48,000 | -$8,000 | -$12,000 | -$30,000 | -$40,000 | $0 |
| Financing cash flow | $19.75M | -$443,000 | $13.95M | $15,000 | $22.39M | $1.17M | $34,000 | $5.00M |
| Depreciation & amortization | $58,000 | $58,000 | $56,000 | $55,000 | $54,000 | $55,000 | $52,000 | $51,000 |
| Stock-based compensation | $952,000 | $563,000 | $334,000 | $197,000 | $307,000 | $170,000 | $152,000 | $113,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.